Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stearns

Showing results (141-150 of 144) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 144 results.
NPJ Regenerative Medicine|March 16, 2023
Myoscaffolds reveal laminin scarring is detrimental for stem cell function while sarcospan induces compensatory fibrosisKristen M Stearns-Reider, Michael R Hicks, Katherine G Hammond, et al.
Hemasphere|January 20, 2025
The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemiaBen Watts, Christopher M Smith, Kathryn Evans, et al.
Pharmacology & Therapeutics|November 7, 2024
Lessons learned from 20 years of preclinical testing in pediatric cancersMalcolm A Smith, Peter J Houghton, Richard B Lock, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Pageof 15

Showing results (141-150 of 144) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 144 results.
NPJ Regenerative Medicine|March 16, 2023
Myoscaffolds reveal laminin scarring is detrimental for stem cell function while sarcospan induces compensatory fibrosisKristen M Stearns-Reider, Michael R Hicks, Katherine G Hammond, et al.
Hemasphere|January 20, 2025
The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemiaBen Watts, Christopher M Smith, Kathryn Evans, et al.
Pharmacology & Therapeutics|November 7, 2024
Lessons learned from 20 years of preclinical testing in pediatric cancersMalcolm A Smith, Peter J Houghton, Richard B Lock, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Pageof 15